Literature DB >> 17017556

Role of cytokines in inflammatory process in Parkinson's disease.

M Sawada1, K Imamura, T Nagatsu.   

Abstract

We investigated whether the cytokines produced in activated microglia in the substantia nigra (SN) and putamen in sporadic Parkinson's disease (PD) are neuroprotective or neurotoxic. In autopsy brains of PD, the number of MHC class II (CR3/43)-positive activated microglia, which were also ICAM-1 (CD 54)-, LFA-1 (CD 11a)-, TNF-alpha-, and IL-6-positive, increased in the SN and putamen during progress of PD. At the early stage activated microglia were mainly associated with tyrosine hydroxylase (TH)-positive neurites in the putamen, and at the advanced stage with damaged TH-positive neurons in the SN. The activated microglia in PD were observed not only in the nigro-striatal region, but also in various brain regions such as the hippocampus and cerebral cortex. We examined the distribution of activated microglia and the expression of cytokines and neurotrophins in the hippocampus of PD and Lewy body disease (LBD). The levels of IL-6 and TNF-alpha mRNAs increased both in PD and LBD, but those of BDNF mRNA and protein drastically decreased specifically in LBD, in which neuronal loss was observed not only in the nigro-striatum but also in the hippocampus. The results suggest activated microglia in the hippocampus to be probably neuroprotective in PD, but those to be neurotoxic in LBD. As an evidence supporting this hypothesis, two subsets of microglia were isolated from mouse brain by cell sorting: one subset with high production of reactive oxygen species (ROS) and the other with no production of ROS. When co-cultured with neuronal cells, one microglia clone with high ROS production was neurotoxic, but another clone with no ROS production neuroprotective. On the other hand, Sawada with coworkers found that a neuroprotective microglial clone in a culture experiment converted to a toxic microglial clone by transduction of the HIV-1 Nef protein with increasing NADPH oxidase activity. Taken together, all these results suggest that activated microglia may change in vivo from neuroprotective to neurotoxic subtsets as degeneration of dopamine neurons in the SN progresses in PD. We conclude that the cytokines from activated microglia in the SN and putamen may be initially neuroprotective, but may later become neurotoxic during the progress of PD. Toxic change of activated microglia may also occur in Alzheimer's disease and other neurodegenerative diseases in which inflammatory process is found.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017556     DOI: 10.1007/978-3-211-45295-0_57

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  115 in total

1.  Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system.

Authors:  B K Binukumar; Amanjit Bal; Kiran Dip Gill
Journal:  Neuromolecular Med       Date:  2011-10-04       Impact factor: 3.843

Review 2.  Role of glial cells in neurotoxin-induced animal models of Parkinson's disease.

Authors:  Hironori Yokoyama; Hiroto Uchida; Hayato Kuroiwa; Jiro Kasahara; Tsutomu Araki
Journal:  Neurol Sci       Date:  2010-11-24       Impact factor: 3.307

Review 3.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

4.  Association study between functional polymorphisms in the TNF-alpha gene and obsessive-compulsive disorder.

Authors:  Carolina Cappi; Renan Kawano Muniz; Aline Santos Sampaio; Quirino Cordeiro; Helena Brentani; Selma A Palácios; Andrea H Marques; Homero Vallada; Eurípedes Constantino Miguel; Luiza Guilherme; Ana Gabriela Hounie
Journal:  Arq Neuropsiquiatr       Date:  2012-02       Impact factor: 1.420

Review 5.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

6.  Interleukin-6 serum levels in patients with Parkinson's disease.

Authors:  Kerly Wollmeister Hofmann; Artur Francisco Schumacher Schuh; Jonas Saute; Raquel Townsend; Daniele Fricke; Renata Leke; Diogo O Souza; Luis Valmor Portela; Márcia Lorena Fagundes Chaves; Carlos R M Rieder
Journal:  Neurochem Res       Date:  2009-02-13       Impact factor: 3.996

Review 7.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

8.  Relationship of plasma cytokines and clinical biomarkers to memory performance in HIV.

Authors:  Stephen Correia; Ronald Cohen; Assawin Gongvatana; Skye Ross; James Olchowski; Kathryn Devlin; Karen Tashima; Bradford Navia; Suzanne Delamonte
Journal:  J Neuroimmunol       Date:  2013-09-27       Impact factor: 3.478

Review 9.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

10.  Lipopolysaccharide-induced epithelial monoamine oxidase mediates alveolar bone loss in a rat chronic wound model.

Authors:  Daisuke Ekuni; James D Firth; Tarun Nayer; Takaaki Tomofuji; Toshihiro Sanbe; Koichiro Irie; Tatsuo Yamamoto; Takashi Oka; Zhenzi Liu; Juergen Vielkind; Edward E Putnins
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.